Wave Life Sciences Ltd. 8K

Wave Life Sciences filed an investor presentation as an 8-K exhibit outlining its RNA medicines pipeline progress, including clinical updates for WVE-007 and WVE-006, plans for WVE-008, and guidance on cash runway and upcoming regulatory milestones.

Wave Life Sciences Ltd. furnished an updated corporate presentation dated July 30, 2026 as Exhibit 99.2 to its Form 8-K, providing an extensive pipeline and strategy update centered on its RNA medicines platforms, including detailed clinical and preclinical data and development plans for its lead programs WVE-007 for obesity (INLIGHT Phase 1 and ongoing Phase 2a), WVE-006 for alpha-1 antitrypsin deficiency (RestorAATion-2 with an anticipated FDA accelerated-approval discussion in late summer 2026), and WVE-008 for PNPLA3 I148M liver disease (with a planned CTA filing in the second half of 2026), along with forward-looking statements about expected cash runway into the third quarter of 2028 and future combination and maintenance trials.

Filing Facts

CIK

1631574

Ticker

WVE

Form

8K

Source Type

fda

Accession

0001193125-26-324917

Alert Tier

5